104.12
1.76 (1.72%)
| Previous Close | 102.36 |
| Open | 102.74 |
| Volume | 5,353,528 |
| Avg. Volume (3M) | 8,294,590 |
| Market Cap | 154,040,336,384 |
| Price / Earnings (TTM) | 76.00 |
| Price / Earnings (Forward) | 35.84 |
| Price / Sales | 8.83 |
| Price / Book | 6.93 |
| 52 Weeks Range | |
| Earnings Date | 22 Jul 2025 - 28 Jul 2025 |
| Profit Margin | 11.58% |
| Operating Margin (TTM) | 20.09% |
| Diluted EPS (TTM) | 1.37 |
| Quarterly Revenue Growth (YOY) | 20.90% |
| Quarterly Earnings Growth (YOY) | 36.20% |
| Total Debt/Equity (MRQ) | 52.16% |
| Current Ratio (MRQ) | 1.45 |
| Operating Cash Flow (TTM) | 3.81 B |
| Levered Free Cash Flow (TTM) | 2.32 B |
| Return on Assets (TTM) | 5.28% |
| Return on Equity (TTM) | 9.50% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Devices (US) | Bearish | Bearish |
| Medical Devices (Global) | Bearish | Bearish | |
| Stock | Boston Scientific Corporation | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | -0.5 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | -2.0 |
| Average | -0.38 |
|
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, kidney stone management, cardiac rhythm management, catheter-directed ultrasound imaging, upper gastrointestinal tract diagnostics, interventional oncology, neuromodulation for chronic pain, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales. |
|
| Sector | Healthcare |
| Industry | Medical Devices |
| Investment Style | Large Core |
| % Held by Insiders | 0.18% |
| % Held by Institutions | 93.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Bollard Group Llc | 31 Mar 2025 | 20,490,826 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 125.00 (Citigroup, 20.05%) | Buy |
| 125.00 (Morgan Stanley, 20.05%) | Buy | |
| 125.00 (Barclays, 20.05%) | Buy | |
| Median | 120.00 (15.25%) | |
| Low | 112.00 (Evercore ISI Group, 7.57%) | Buy |
| Average | 119.67 (14.94%) | |
| Total | 9 Buy | |
| Avg. Price @ Call | 102.56 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Leerink Partners | 16 Jun 2025 | 118.00 (13.33%) | Buy | 101.49 |
| Needham | 28 May 2025 | 115.00 (10.45%) | Buy | 104.51 |
| 24 Apr 2025 | 115.00 (10.45%) | Buy | 101.14 | |
| Citigroup | 22 May 2025 | 125.00 (20.05%) | Buy | 104.50 |
| Morgan Stanley | 16 May 2025 | 125.00 (20.05%) | Buy | 106.04 |
| Barclays | 25 Apr 2025 | 125.00 (20.05%) | Buy | 101.90 |
| Baird | 24 Apr 2025 | 120.00 (15.25%) | Buy | 101.14 |
| Evercore ISI Group | 24 Apr 2025 | 112.00 (7.57%) | Buy | 101.14 |
| RBC Capital | 24 Apr 2025 | 120.00 (15.25%) | Buy | 101.14 |
| Truist Securities | 24 Apr 2025 | 117.00 (12.37%) | Buy | 101.14 |
| 11 Apr 2025 | 113.00 (8.53%) | Buy | 93.67 | |
| Show more | ||||
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Jul 2025 | Announcement | Boston Scientific announces conference call discussing second quarter 2025 results |
| 01 May 2025 | Announcement | Boston Scientific announces upcoming investor conference schedule |
| 24 Apr 2025 | Announcement | Second phase of ADVANTAGE AF study of FARAPULSE™ Pulsed Field Ablation System meets primary safety and efficacy endpoints |
| 23 Apr 2025 | Announcement | Boston Scientific Chief Financial Officer (CFO) Dan Brennan to retire; Jon Monson, senior vice president, Investor Relations to succeed Brennan |
| 23 Apr 2025 | Announcement | Boston Scientific announces results for first quarter 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |